Observational studyInfection2025
Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
Observational study in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Ceftazidime-Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae.Infectious diseases and therapy · 2026Article
- Genetic signatures of lung cancer: association and biomarker potential of EGFR, KRAS, and HER2 polymorphisms.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Pharmaceutical innovation in advanced nanomedicine for the treatment of hypervirulent and multidrug-resistant Klebsiella pneumoniae infections.Archives of microbiology · 2026Review
- Adaptive Evolution in Aminoacyl-tRNA Synthetases Drives Antibiotic Tolerance and Resistance in Clinical Klebsiella pneumoniae Isolates.Molecular biotechnology · 2026Article
- Covalent and non-covalent synergy in molecularly imprinted polymer-coated hollow nanocages for selective electrochemical recognition of azithromycin.Mikrochimica acta · 2026Article
- Biogenic Synthesis of Silver Nanoparticles by Deinococcus radiodurans for Efficient Photocatalytic Biotransformation of Dyes.Biotechnology and applied biochemistry · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2026Article
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Computer-aided design, molecular dynamics simulations and in-vitro inhibitory potential of piperazine bridged bis-thiadiazole benzothioate derivatives against platelet-derived endothelial cell growth factor.Journal of computer-aided molecular design · 2026Article
- Comparative efficacy and safety of colistin sulfate versus polymyxin B in critically ill patients with carbapenem-resistant gram-negative infections: a pilot inverse probability of treatment weighting-based retrospective cohort study.BMC infectious diseases · 2026Article
- Treatment Options for Metallo-Beta-Lactamase-ProducingInternational journal of molecular sciences · 2026Review
- Ceftazidime-avibactam versus polymyxin B for carbapenem-resistant gram-negative bacteria-associated post-neurosurgical meningitis: a retrospective comparative study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Nanomaterial-nucleic acid probe synergy: accelerating rapid pathogen detection and antimicrobial susceptibility testing in bloodstream infections.Folia microbiologica · 2026Review
- Comparison of the Efficacy and Safety of Intravenous Ceftazidime-Avibactam and Intrathecal/Intraventricular Polymyxin B Sulfate in the Treatment of CNS Infections Caused by KPC-Antibiotics (Basel, Switzerland) · 2026Article
- Assessment of aminoglycosides and β-lactam resistance genes among uropathogens; a prospective-cross sectional study.BMC urology · 2026Article
- Seroprevalence and risk factors associated with bluetongue and Schmallenberg virus infections in domestic small ruminants in Türkiye.Tropical animal health and production · 2026Article
- Article
- Combined application of 5-ALA and nitric oxide improves lead detoxification and antioxidant defense in barley.Biodegradation · 2026Article
- Carbapenem-resistant hypervirulentFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesIn this retrospective observational multicenter study, we aimed to assess efficacy and mortality between ceftazidime/avibactam (CAZ/AVI) or polymyxin B (PMB)-based regimens for the treatment of Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections, as well as identify potential risk factors.
methodsA total of 276 CRKP-infected patients were enrolled in our study. Binary logistic and Cox regression analysis with a propensity score-matched (PSM) model were performed to identify risk factors for efficacy and mortality.
resultsThe patient cohort was divided into PMB-based regimen group (n = 98, 35.5%) and CAZ/AVI-based regimen group (n = 178, 64.5%). Compared to the PMB group, the CAZ/AVI group exhibited significantly higher rates of clinical efficacy (71.3% vs. 56.1%; p = 0.011), microbiological clearance (74.7% vs. 41.4%; p < 0.001), and a lower incidence of acute kidney injury (AKI) (13.5% vs. 33.7%; p < 0.001). Binary logistic regression revealed that the treatment duration independently influenced both clinical efficacy and microbiological clearance. Vasoactive drugs, sepsis/septic shock, APACHE II score, and treatment duration were identified as risk factors associated with 30-day all-cause mortality. The CAZ/AVI-based regimen was an independent factor for good clinical efficacy, microbiological clearance, and lower AKI incidence.
conclusionsFor patients with CRKP infection, the CAZ/AVI-based regimen was superior to the PMB-based regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.